Literature DB >> 1561798

Predicting survival and recurrence in localized melanoma: a multivariate approach.

S J Soong1, H M Shaw, C M Balch, W H McCarthy, M M Urist, J Y Lee.   

Abstract

Several clinical and pathologic factors appear to affect melanoma recurrence and survival. While much attention has been directed at identifying prognostic factors, few researchers have developed predictive models for survival and recurrence. Two major clinical questions are of interest in the management of melanoma: 1) what is the patient's chance of surviving for a given period, e.g., 5 or 10 years, after diagnosis of melanoma; and 2) after a patient has been disease free for a period of time, e.g., 5 years, what is his or her chance of melanoma recurrence or death in the following interval, e.g., 5 years or 10 years. In this paper, a generalized multivariate prognostic model to address both of these clinical questions is presented. Tables of the estimated probabilities of melanoma recurrence and death for prognostic subgroups are shown to facilitate prediction of an individual patient's outcome. The model was based on a database of 4,568 patients with localized melanoma, one of the largest melanoma databases in the world with detailed clinical and pathologic information, and long-term follow-up. Tumor thickness at diagnosis was the single most important prognostic factor for all outcomes. Tumor ulceration, Clark's level, lesion location, and sex had an impact on overall survival from diagnosis for some of the subgroups defined by tumor thickness. Tumor thickness at diagnosis was strongly indicative of melanoma recurrence and death even after a disease free interval of 2, 5, or 10 years.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1561798     DOI: 10.1007/bf02071520

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  2 in total

1.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

2.  A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.

Authors:  C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

  2 in total
  17 in total

1.  Malignant melanoma of the skin: long-term follow-up and time to first recurrence.

Authors:  Annika M Hohnheiser; Olaf Gefeller; Jonas Göhl; Gerold Schuler; Werner Hohenberger; Susanne Merkel
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

2.  Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

Authors:  Sanjiv S Agarwala; Sandra J Lee; Waiki Yip; Uma N Rao; Ahmad A Tarhini; Gary I Cohen; Douglas S Reintgen; Terry L Evans; Joanna M Brell; Mark R Albertini; Michael B Atkins; Shaker R Dakhil; Robert M Conry; Jeffrey A Sosman; Lawrence E Flaherty; Vernon K Sondak; William E Carson; Michael G Smylie; Alberto S Pappo; Richard F Kefford; John M Kirkwood
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

3.  Parametric modeling of localized melanoma prognosis and outcome.

Authors:  Shouluan Ding; Seng-Jaw Soong; Hui-Yi Lin; Renee Desmond; Charles M Balch
Journal:  J Biopharm Stat       Date:  2009-07       Impact factor: 1.051

4.  Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.

Authors:  Jan Zakrzewski; Laurel N Geraghty; Amy E Rose; Paul J Christos; Madhu Mazumdar; David Polsky; Richard Shapiro; Russell Berman; Farbod Darvishian; Eva Hernando; Anna Pavlick; Iman Osman
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

5.  Clinical guidelines for the recognition of melanoma of the foot and nail unit.

Authors:  Ivan R Bristow; David Ar de Berker; Katharine M Acland; Richard J Turner; Jonathan Bowling
Journal:  J Foot Ankle Res       Date:  2010-11-01       Impact factor: 2.303

6.  Development of a practical guide for the early recognition for malignant melanoma of the foot and nail unit.

Authors:  Ivan R Bristow; David Ar de Berker
Journal:  J Foot Ankle Res       Date:  2010-09-28       Impact factor: 2.303

7.  Sentinel lymph node metastasis in anal melanoma: a case report.

Authors:  Huey Y Tien; Kelly M McMasters; Michael J Edwards; Celia Chao
Journal:  Int J Gastrointest Cancer       Date:  2002

8.  Thin melanomas: predictive lethal characteristics from a 30-year clinical experience.

Authors:  Matthew F Kalady; Rebekah R White; Jeffrey L Johnson; Douglas S Tyler; Hilliard F Seigler
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

9.  Melanoma survivorship: research opportunities.

Authors:  Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

10.  Dermoscopy as a technique for the early identification of foot melanoma.

Authors:  Ivan R Bristow; Jonathan Bowling
Journal:  J Foot Ankle Res       Date:  2009-05-12       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.